LENZ Therapeutics (LENZ) Other financing activities (2021 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Other financing activities of $14000.0 for Q1 2026, down 68.18% year-over-year from $44000.0 in Q1 2025, and down 97.84% quarter-over-quarter from $648000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Other financing activities (2021 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Other financing activities for 6 consecutive years, with $14000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 68.18% year-over-year to $14000.0; the TTM figure through Mar 2026 stood at $843000.0 (down 76.92% YoY), while the FY2025 annual figure was $873000.0, down 78.38% from the prior year.
- Other financing activities eased to $14000.0 in Q1 2026 per LENZ's latest filing, from $648000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $4.0 million in Q4 2024 and bottomed at -$3.8 million in Q3 2024.
- Historically, Other financing activities has averaged $447500.0 across 5 years, with a median of $199500.0 in 2023.
- Annual changes were most pronounced in 2022 — Other financing activities jumped 9014.29% — and 2025, when it slumped 94.26%.
- LENZ Therapeutics' Other financing activities stood at $638000.0 in 2022, then slumped by 68.18% to $203000.0 in 2023, then jumped by 1889.16% to $4.0 million in 2024, then slumped by 83.95% to $648000.0 in 2025, then tumbled by 97.84% to $14000.0 in 2026.
- Business Quant data shows LENZ's Other financing activities at $14000.0 in Q1 2026, $648000.0 in Q4 2025, and -$15000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 381,000.00 |
| Jun 30, 2026 | 381,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Dec 31, 2025 | 648,000.00 |
| Dec 31, 2025 | 648,000.00 |
| Sep 30, 2025 | -15,000.00 |
| Sep 30, 2025 | -15,000.00 |
| Jun 30, 2025 | 196,000.00 |
| Jun 30, 2025 | 196,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 4.04 Mn |
| Dec 31, 2024 | 4.04 Mn |
| Sep 30, 2024 | -3.84 Mn |
| Sep 30, 2024 | -3.84 Mn |
| Jun 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.41 Mn |
| Mar 31, 2024 | 430,000.00 |
| Mar 31, 2024 | 430,000.00 |